Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VCYT
stocks logo

VCYT

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
120.90M
+5.66%
0.299
-0.33%
124.35M
+7.33%
0.322
-2.34%
132.01M
+11.28%
0.375
+4.18%
Estimates Revision
The market is revising Upward the revenue expectations for Veracyte, Inc. (VCYT) for FY2025, with the revenue forecasts being adjusted by 0.74% over the past three months. During the same period, the stock price has changed by -7.88%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.74%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+8.23%
In Past 3 Month
Stock Price
Go Down
down Image
-7.88%
In Past 3 Month
8 Analyst Rating
up Image0
Wall Street analysts forecast VCYT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCYT is 39.67 USD with a low forecast of 29.00 USD and a high forecast of 45.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
1 Sell
Strong Buy
up Image0
Current: 26.605
sliders
Low
29.00
Averages
39.67
High
45.00
up Image0
Current: 26.605
sliders
Low
29.00
Averages
39.67
High
45.00
UBS
Buy
downgrade
$49 -> $42
2025-05-08
Reason
UBS
Price Target
$49 -> $42
2025-05-08
downgrade
Buy
Reason
UBS lowered the firm's price target on Veracyte to $42 from $49 and keeps a Buy rating on the shares. UBS sees durable growth in Veracyte's core products, as well as long-term growth potential from minimal residual disease testing, the analyst tells investors in a research note.
Guggenheim
Subbu Nambi
Strong Buy
Maintains
$45 → $37
2025-04-09
Reason
Guggenheim
Subbu Nambi
Price Target
$45 → $37
2025-04-09
Maintains
Strong Buy
Reason
Guggenheim lowered the firm's price target on Veracyte to $37 from $45 and keeps a Buy rating on the shares. The firm adjusted its 2025 revenue and test volumes based on recent management commentary, updated its model for the latest 10K release post-earnings and revised its price target to reflect multiple compression in the peer group.
Stephens & Co.
Mason Carrico
Buy
Reiterates
$45
2025-03-26
Reason
Stephens & Co.
Mason Carrico
Price Target
$45
2025-03-26
Reiterates
Buy
Reason
Craig-Hallum
John Wilkin
Strong Buy
Initiates
$45
2025-03-20
Reason
Craig-Hallum
John Wilkin
Price Target
$45
2025-03-20
Initiates
Strong Buy
Reason
Craig-Hallum initiated coverage of Veracyte with a Buy rating and $45 price target.
Needham
Mike Matson
Strong Buy
Reiterates
$51
2025-02-25
Reason
Needham
Mike Matson
Price Target
$51
2025-02-25
Reiterates
Strong Buy
Reason
Guggenheim
Subbu Nambi
Strong Buy
Reiterates
$45
2025-02-25
Reason
Guggenheim
Subbu Nambi
Price Target
$45
2025-02-25
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Veracyte Inc (VCYT.O) is 21.53, compared to its 5-year average forward P/E of -23.16. For a more detailed relative valuation and DCF analysis to assess Veracyte Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-23.16
Current PE
21.53
Overvalued PE
1290.95
Undervalued PE
-1337.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-60.35
Current EV/EBITDA
17.29
Overvalued EV/EBITDA
86.54
Undervalued EV/EBITDA
-207.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
8.05
Current PS
4.28
Overvalued PS
12.90
Undervalued PS
3.20

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

VCYT News & Events

Events Timeline

(ET)
2025-05-28
16:16:49
Veracyte to present multiple abstracts at ASCO
select
2025-05-07 (ET)
2025-05-07
17:16:50
Veracyte backs FY25 testing revenue view $470M-$480M
select
2025-05-07
17:16:16
Veracyte reports Q1 adjusted EPS 31c, consensus 20c
select
Sign Up For More Events
Sign Up For More Events

News

Preview
5.0
06-21Benzinga
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet

  • Ark Invest's Significant Trades: On Friday, Ark Invest, led by Cathie Wood, made notable trades focusing on tech and hospitality sectors, including purchases of shares in Airbnb, Advanced Micro Devices, and Shopify, signaling confidence in these industries' recoveries.

  • Sales and Other Investments: The firm also sold off shares of Circle Internet Group and Adaptive Biotechnologies while acquiring additional shares in companies like BWX Technologies and Robinhood, reflecting a strategic shift in their investment portfolio.

Preview
5.0
06-07Benzinga
Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems

  • Ark Invest's Recent Trades: On Friday, Ark Invest made notable trades including a significant purchase of 30,771 shares of Veracyte Inc. (VCYT) valued at approximately $844,971, while also selling shares of 3D Systems Corp. (DDD) and Avidxchange Holdings Inc. (AVDX), indicating a strategic shift in their investment approach.

  • Impact on ETFs: The trades affected various Ark Invest ETFs, with the ARK Innovation ETF (ARKK) increasing its stake in Veracyte, while the ARK Autonomous Technology & Robotics ETF (ARKQ) and ARK Space Exploration & Innovation ETF (ARKX) reduced their holdings in 3D Systems, and the ARK Fintech Innovation ETF (ARKF) sold shares of Avidxchange.

Preview
9.0
05-29Yahoo Finance
Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO

  • Veracyte's Research Presentation: Veracyte, Inc. will present eight new studies at the ASCO 2025 annual meeting, showcasing advancements in personalized cancer care for prostate and bladder cancers, including significant findings on treatment benefits based on genetic signatures.

  • Decipher Technology Impact: The Decipher Prostate and Bladder genomic classifiers are proving valuable in guiding treatment decisions, with the potential for more targeted therapies based on molecular subtypes identified through their GRID platform.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Veracyte Inc (VCYT) stock price today?

The current price of VCYT is 26.605 USD — it has increased 1.01 % in the last trading day.

arrow icon

What is Veracyte Inc (VCYT)'s business?

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

arrow icon

What is the price predicton of VCYT Stock?

Wall Street analysts forecast VCYT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCYT is 39.67 USD with a low forecast of 29.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Veracyte Inc (VCYT)'s revenue for the last quarter?

Veracyte Inc revenue for the last quarter amounts to 114.47M USD, increased 18.20 % YoY.

arrow icon

What is Veracyte Inc (VCYT)'s earnings per share (EPS) for the last quarter?

Veracyte Inc. EPS for the last quarter amounts to 0.09 USD, decreased -550.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Veracyte Inc (VCYT)'s fundamentals?

The market is revising Upward the revenue expectations for Veracyte, Inc. (VCYT) for FY2025, with the revenue forecasts being adjusted by 0.74% over the past three months. During the same period, the stock price has changed by -7.88%.
arrow icon

How many employees does Veracyte Inc (VCYT). have?

Veracyte Inc (VCYT) has 824 emplpoyees as of July 08 2025.

arrow icon

What is Veracyte Inc (VCYT) market cap?

Today VCYT has the market capitalization of 2.06B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free